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Abstract: Intensive glycemic control using insulin therapy may be appropriate for many healthy
older adults to reduce premature mortality and morbidity, improve quality of life, and reduce
health care costs. However, frail elderly people are more prone to develop complications from
hypoglycemia, such as confusion and dementia. Overall, older persons with type 2 diabetes
mellitus are at greater risk of death from cardiovascular disease (CVD) than from intermittent hyperglycemia; therefore, diabetes management should always include CVD prevention
and treatment in this patient population. Pharmacists can provide a comprehensive medication review with subsequent recommendations to individualize therapy based on medical and
cognitive status. As part of the patient’s health care team, pharmacists can provide continuity
of care and communication with other members of the patient’s health care team. In addition,
pharmacists can act as educators and patient advocates and establish patient-specific goals to
increase medication effectiveness, adherence to a medication regimen, and minimize the likelihood of adverse events.
Keywords: glycemic control, hyperglycemia, continuity of care, hypertension and cardiovascular
disease, elderly, type 2 diabetes, pharmacist
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More than 20% of elderly Americans (65 years or older) have type 2 diabetes mellitus
(T2DM).1 T2DM is associated with increased morbidity and mortality in the elderly,2
and half of elderly patients receiving diabetes treatment do not achieve adequate
glycemic control.3 Although glycemic control is important, elderly patients with
diabetes are more likely to benefit from the additional treatment for hypertension and
cardiovascular disease (CVD) than with only tight glycemic control.1 Compared with
a younger cohort, older Americans with diabetes are more likely to have geriatric
syndrome, which is a cluster of conditions that include injurious falls, cognitive impairment, and depression.4 These conditions can complicate the management of diabetes
and increase the likelihood of hypoglycemia, confusion, and dementia. As part of the
patient’s health care team, pharmacists can act as educators and patient advocates and
establish patient-specific goals to increase medication effectiveness and adherence to
their medication regimen, and minimize adverse events. For example, pharmacists
who participated in the Diabetes Ten City Challenge (DTCC) provided coaching, used
evidence-based diabetes care guidelines, and implemented patient self-management
strategies, which resulted in reductions in glycosylated hemoglobin, low-density
lipoprotein cholesterol, and systolic blood pressure in 573 patients with diabetes after
1 year of follow-up.5 Pharmacists referred patients to physicians for further assessment,
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contacted other providers (such as a dietitian) for intensive
nutrition education, or communicated with diabetes education
centers for additional education support.

Special considerations for elderly
patients with diabetes
Elderly persons are more likely to develop and be more
susceptible to diabetes-related complications.1 In particular,
this population should be evaluated for complications that
develop over short periods of time and/or for those that
would significantly impair functional status, such as vision
and lower-extremity complications (ie, peripheral neuropathy and subsequent diabetic foot infections). Diabetes
treatment-related complications may be more problematic
in elderly persons than in the nonelderly; for example,
hypoglycemia may aggravate dementia6 and can increase
the risk of falls. Elderly persons may be at greater risk than
younger patients for comorbid conditions such as depression,
which can lead to treatment apathy and reduced medication
effectiveness.
Adherence to a prescribed medication regimen should
not be assumed. About 30% of Medicare patients with
medication coverage are nonadherent to their medication
regimens for financial reasons.7 Patients who repeatedly miss
medical appointments may be at increased risk for nonadherence and will likely require diligent follow-up measures
to resolve underlying issues. A comprehensive medication
review by the pharmacist, which includes medication adherence and individual strategies to decrease nonadherence,
can help identify other medication-related issues. Elderly
patients may not be able to read their medication instructions or understand how to take the medications; these issues
can be addressed with additional education and repeated
interventions. Taking multiple drugs several times a day can
lead to medication errors, adverse events, reduced medication efficacy, increased costs, and poor regimen adherence.8
Polypharmacy is common, as elderly persons tend to keep
medications that were prescribed years ago, and may keep
medications that were switched to another drug within the
same drug class after a hospitalization. Medication reconciliation should include discontinuing medications that are
a therapeutic duplication, or that contain the same active
ingredient but were prescribed as a different formulation
or as part of a combination drug.
Diabetes self-management weaknesses and the patient’s
history of hypoglycemic events should be addressed by a
pharmacist and other health care providers so action can
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be taken to prevent future events. Assessing for cognitive
decline or depression is necessary to differentiate these
disorders from symptoms related to hypoglycemia. If a
patient is diagnosed with and treated for depression, the
patient should be reevaluated to assess treatment efficacy
and symptom improvement. Working with the patient and
prescribers to simplify treatment regimens may increase
medication regimen adherence, minimize adverse effects,
and increase medication effectiveness.

Diabetes treatment guidelines
for the elderly
Treatment goals should be developed and achieved in line
with the elderly patient’s medical, functional, social, and
financial status.4 Aggressive treatment is appropriate for
most healthy older adults to reduce premature mortality
and morbidity, improve quality of life, and reduce health
care costs.1 These patients may benefit from regimens
that include insulin to allow dosage adjustment with food
intake and level of exercise. However, due to a patient’s
advancing age, treatment decisions become more complex, and their capacity to cope with adverse effects and
complicated treatment regimens declines. To minimize the
risk of hypoglycemia and associated complications such as
falls or confusion, less aggressive fasting glucose targets
may be necessary for frail elderly patients9 (those with an
unintentional weight loss of 10 pounds in the past year,
chronic exhaustion, and low grip strength, walking speed,
and physical activity).10 For these frail elderly patients,
treatment selection should include therapies with a low
risk of hypoglycemia, such as metformin or an incretin
mimetic; therapies with a high risk of hypoglycemia,
such as long-acting sulfonylureas (ie, chlorpropamide or
glyburide), should be avoided.
The long-term benefits of tight control of fasting blood
glucose will likely not be observed in patients with advanced
age. Cardiovascular disease is a leading cause of death in
this population,11 and a greater reduction in morbidity and
mortality is expected by controlling CVD risk factors.12
Elevated postprandial glucose (PPG) levels may increase the
risk of CVD.13 Data on PPG control in the elderly are limited;
however, selecting drug therapy that targets PPG should be
considered to further reduce CVD risk. Elderly patients and
caregivers should be educated about controlling CVD risk
factors by discussing the importance of smoking cessation
and blood pressure control. Pharmacists can provide continuity of care by communicating changes in over-the-counter

Journal of Multidisciplinary Healthcare 2011:4

Dovepress

Management of type 2 diabetes mellitus in the elderly

medications or herbal therapies to the patient’s prescriber
and other health care team members.

Treatment options for diabetes
in the elderly
Dietary changes may only moderately help with glycemic
control in the elderly. These patients may have defective
dentition, loss of taste/poor appetite, or an unwillingness
to change a lifetime of eating habits.9 Elderly patients
should consult with a dietitian to create a well balanced
diet that facilitates weight loss (if needed) and helps maintain glycemic control.14 Exercise should be consistent and
based on what the patient can tolerate. Preferably, these

patients should walk or swim for 30 minutes a day to
maintain muscle conditioning.9 Foot and eye care should
be discussed with the patient. Pharmacists should review
nonpharmacologic therapy, including lifestyle modifications, to determine if any changes could be made to
improve effectiveness of recommended nonpharmacologic
interventions. In addition, the pharmacist could discuss
daily foot care, and could conduct a basic foot exam to
assess pedal pulses, abnormalities in anatomy, and changes
in sensation.
Pharmacologic treatment options are briefly presented
in Table 1.1,4,9,14–19 To assess the effectiveness and safety
of antihyperglycemic medications, the pharmacist should

Table 1 Summary points for drugs used to treat diabetes in the elderly
Drug class/name

Possible drug or disease
interactions

Adverse events that
may limit use

Important notes

Alpha-glucosidase
inhibitors9

Erratic oral intake; must
take with main meals to be
effective
Frequent daily dosing
Concomitant use with
insulin secretagogues
increases risk of
hypoglycemia
Concomitant use with
insulin secretagogues
increases risk of
hypoglycemia

Gastrointestinal effects

Adjust dose with renal or liver dysfunction

Hypoglycemia, weight gain
Headache, infection,
dermatologic effects16

Insulins17,18

Erratic oral intake
can increase risk of
hypoglycemia; low vision
and dexterity may limit use
of vial and syringes, clinician
inertia

Hypoglycemia

Metformin1

Impaired renal function

Lactic acidosis (rare but serious),
gastrointestinal effects

Pioglitazone14

Class III and class IV
congestive heart failure

Sulfonylureas4

Erratic oral intake can
increase risk of hypoglycemia
with long-acting agents

Weight gain, fluid
retention, peripheral edema,
fractures among women19
Hypoglycemia, weight gain

Rapid onset
• Effects are glucose dependent, so low risk
for hypoglycemia
• Weight neutral
• Target PPG levels
• Effects are glucose dependent, so low risk
for hypoglycemia
• Weight loss
• Target PPG levels
• Decrease blood pressure; improve other
CVD markers16
• Better glycemic control if difficulty adhering
to oral medications, receiving multiple oral
medications, or not achieving glycemic targets
than with oral medications alone
• Early use may restore and improve beta-cell
function
• Insulin pens increase adherence for patients
with low vision and/or dexterity issues
• Measure serum creatinine and liver function
periodically and with any increase in dose
• Weight neutral versus placebo19
• Avoid initiating in patients $80 years of age
unless creatinine clearance is within normal
limits
Hypoglycemia rare

Meglitinides1
Incretin therapies
DPP-4 inhibitors15

Incretin therapies
GLP-1 agonists15

Gastrointestinal effects (less than
alpha-glucosidase inhibitors),15
pancreatitis, immune reactions
(incidence less with liraglutide
than exenatide)16

Avoid long-acting sulfonylureas; short-acting
(ie, glipizide) minimize risk of nocturnal
hypoglycemia, and may also help avoid
hypoglycemia in patients with erratic oral intake

Abbreviations: CVD, cardiovascular disease; DPP-4, dipeptidyl peptidase IV; GLP-1, glucagon-like peptide 1; NPH, neutral protamine Hagedorn; PPG, postprandial glucose.
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carefully monitor glucose levels (including PPG), weight,
renal function, and blood pressure. Elderly persons are more
likely to have renal dysfunction than other adults. Therefore,
medications such as metformin should be used with caution
in these patients because of the risk of developing lactic acidosis, a rare but potentially fatal adverse effect that is more
common in those with renal dysfunction. Gastrointestinal
adverse effects can be debilitating in the older person. For
example, glucagon-like peptide 1 (GLP-1) agonists are
associated with treatment-limiting nausea; however, these
agents have a low risk of hypoglycemia. The pharmacist
can discuss ways to reduce or manage drug-induced nausea or recommend switching to a therapy with a low risk
of this adverse effect. Clinician inertia, delaying insulin
therapy because of fears of hypoglycemia, and perceived
lack of benefit can also be addressed by a pharmacist by
communicating patient-specific needs to other members of
the health care team.
As an individual ages, beta-cell function declines.
Studies suggest that early use of insulin in the elderly

restores and improves beta-cell function and induces disease
remission.18,20 Simple insulin regimens with premeasured
doses and easier injection systems (eg, insulin pens with
easy-to-set dosages) are preferred in the elderly patient.21
Timing of insulin doses relative to meals and adjusting doses
based on meal content and caloric intake minimize the risk of
hypoglycemia. For some elderly people, two daily injections
using premixed insulin analog preparations or a long-acting
insulin analog for basal control may be preferred to multiple
oral medications. Fasting and post-prandial glucose levels
should be monitored and assessed to determine if target
levels have been obtained. If control is unsatisfactory, a
dose of rapid-acting insulin analog for prandial glucose
control during the main meal could be added to the basal
regimen. For the healthy older person, a combination of
rapid- and long-acting insulin analogs would provide tight
glycemic control and allow dosing flexibility. Elderly people
who are not frail are more likely to benefit from long-term
tight glycemic control, which is associated with a reduced
risk of diabetes-related microvascular complications and

Table 2 Pharmacist-provided patient care and associated outcomes in older patients with type 2 diabetes mellitus
Study

Methods

Results

Cranor et al

• Quasi-experimental, longitudinal, pre and post cohort
trial design
• 12 community-based pharmacists trained in
diabetes education
• Asheville Project
• Change in clinical and economic outcomes before
and after up to 5 years of implementation of services

Fera et al5

• Prospective, observational, pre- and post-cohort
trial design
• Collaborative practice model
• Community-based pharmacists
• Evidence-based guidelines
• Clinical and economic outcomes
• Diabetes Ten City Challenge
• Change in clinical and economic outcomes before
and after 1 year of implementation of services
• Prospective, randomized, controlled trial
• Pharmacist management versus usual medical care
• Change in A1c after 1 year of care
• Poorly controlled diabetes (A1c . 9%)
• One pharmacist with advanced diabetes education training
• Intervention consisted of targeted patient outreach
program plus medication management, patient education,
disease control by a pharmacist
• Control group used targeted patient outreach programs
and registries

• n = 620 financial cohort, n = 565 clinical cohort
• Baseline median age 48 years
• Median A1c decreased by 0.8% after first follow-up
visit (P , 0.001)
• LDL-C decreased by 2.5 mg/dL after the first follow-up
visit (P = 0.13)
• Total direct medical costs decreased by US$1662–$3356
per patient per year depending on the follow-up year,
despite increases in mean prescription costs
• N = 573
• 42% were 60 years or older
• Mean A1c decreased by 0.4% (P = 0.002)
• Mean LDL-C decreased by 4 mg/dL (P , 0.001)
• Mean SBP decreased by 3 mmHg (P , 0.001)
• Average total health care costs per patient per year
decreased by US$1079 (7.2%)
• Influenza vaccination rate increased by 33%
• Foot examination rate increased by 40%
• N = 103 (intervention group n = 52, control group n = 51)
• Mean age 49 years
• Mean A1c decreased by 1.5% for the intervention group
and 0.4% for the control group (P = 0.06)
• A1c decreased by at least 1% for 67.3% versus 41.2%,
respectively (P = 0.02)
• Male and nonwhite patients had greater improvement
in A1c than female or white patients

24

Jameson and Baty25

Abbreviations: A1c, glycosylated hemoglobin; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure.
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amputations. In addition, long-acting insulin analogs do not
have the pronounced peak observed with neutral protamine
Hagedorn (NPH) insulin and are less likely to produce nocturnal hypoglycemia.22
Pharmacists are in a key position to improve diabetes
control in this potentially high-risk population. In observational and controlled trials, medication management
and diabetes education provided by the pharmacist has
been reported to improve A1c, blood pressure, and lipid
parameters.23 In addition, these services increase patient
satisfaction and decrease health care costs. The DTCC is
an example of how pharmacy practice around the country
is evolving to include patient education, medication therapy
management, basic physical assessment, routine patient
and caregiver follow up, and constant collaboration with
other health care providers.5 A brief list of recently published primary literature evaluating clinical outcomes and
pharmacist-provided diabetes care of the older patient is
provided in Table 2.5,24,25
Older persons with diabetes are at greater risk of death
from CVD than from intermittent hyperglycemia. Frail
elderly people are more prone to develop complications from
hypoglycemia, such as confusion and dementia. Continuity
of care, communication with other members of the patient’s
health care team, and a comprehensive medication review
by the pharmacist, with subsequent recommendations to
individualize therapy based on medical and cognitive status, will minimize adverse effects and optimize treatment
effectiveness.
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